Lapatinib benefits women with HER2-positive breast cancer

[News]

Findings published in the December 1, 2008, issue of Clinical Cancer Research , a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit.

More... (http://www.news-medical.net/?id=43681)